Nephrectomy is often the initial treatment for renal-cell cancer (RCC), but systemic therapy is frequently required for advanced RCC. Single-agent targeted therapies are only somewhat effective, which led to the development of immunotherapies and combination therapies (which include immunotherapies). Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss the clinical advantages of combination therapies in patients with advanced RCC.